Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
about
Cardiovascular safety of anti-diabetic drugsThe treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesHypoglycemic agents and potential anti-inflammatory activitySodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusUpdate on the treatment of type 2 diabetes mellitusPractical combination therapy based on pathophysiology of type 2 diabetesSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewMesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic NephropathyA comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Empagliflozin in the treatment of type 2 diabetes: evidence to dateSodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.How much is too much? Outcomes in patients using high-dose insulin glargine.Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesResearch into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studiesDapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.My Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetesIpragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).Combination therapy when metformin is not an option for type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns.Implications of the EMPA-REG Trial for Clinical Care and Research.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
P2860
Q26741082-DEAF924A-B94E-4585-9BCF-C086D8FEA831Q26744317-4045981E-31C5-41DB-9D66-47C4A4557660Q26750414-07E5A768-54A3-4832-90E3-8EF3C118621EQ26767263-B31759E7-9E51-4FE0-89B6-57B546069FACQ26782225-74CC0CC5-24B0-419E-8127-ABCC121493DFQ28073342-DED930EB-5897-417F-AEC1-18C6B9FC219CQ28076530-DB38623C-E733-4E5C-A1B8-F3A97EC92D1AQ28079134-F7C4C7F6-9917-49D8-8E9A-5C24520DA0F1Q28354224-8690EB73-F9F8-4339-866F-A62C14AE5267Q33560279-E11B5C70-72CA-40AB-A9E5-62D6020D11ADQ33696974-5744517B-E096-462A-A200-97E95886CD13Q33763305-1FC22BF8-E6E6-4D3C-8730-B0E3A3B9BB91Q33882438-384A63B0-F33D-4455-BC17-D2BD8E80BFD6Q34502358-CA210F50-57CB-4C99-B60A-DE58C3FAEDB6Q34726437-BE0072A3-C3A7-4B67-B023-1F987C20C487Q35852679-A21F8385-2BC2-4205-8CB3-6ECEF91707E1Q36303346-E6FB5167-4B32-4536-8B55-9DA5E28A1ADFQ36536807-B3C62C31-DC7E-4C9A-8E86-6F6A4385D69AQ36765350-34E0C85C-3D77-46D2-9BD1-633C8C125457Q37075620-59B00F29-03A3-4D60-8588-97372A02B3B6Q37097189-597364E4-D035-4A1B-8063-5657A710BEDCQ37354187-7F1B1CF5-CC90-44F5-8F3A-4C817A1A2A9DQ37586607-CB831D44-2FCA-4BA5-95BE-032DF630AB9BQ37588842-82E3DB36-5F37-48B9-A627-ACC89EA36361Q37588847-75E1686C-0EBD-4CF7-B28B-ED680B9C6B7CQ37594479-A01D7F78-B020-46BC-8889-CFABA5D911B8Q37670082-A57E6705-18FC-4106-B2A6-EEA160F360D7Q37722896-3A831E14-BEDF-423A-B586-7F5B7B95E7ABQ37741752-F1E287D2-D2CB-4519-B757-DF3D45B201CDQ38340949-D73CA8AE-F0CF-43FB-9534-787F3DD8FCBDQ38371417-6C7523F4-3601-4453-8CD1-3B5967791EB5Q38377267-01004BBD-5714-46B3-9E0E-05A99EF07477Q38389823-95E7B513-DD7C-41BB-9C70-D602872A975CQ38429845-94A64568-DC9E-476A-9B26-4CD04E5EC109Q38468017-118E5EF0-89AE-4ACF-B01F-3EEB46E20638Q38619164-0ED995E3-E9FC-4B86-96F7-3A8F7F8795C8Q38635763-6B169EB7-54B8-4433-AC8E-95EF1AA7019DQ38734956-684523A7-AFEE-4120-99EC-E97F1154EA81Q38798623-DD009B1F-CD39-4039-B1E1-6C8626C76E3CQ38827756-57FC47F1-C223-4DBA-AAA2-4D4486D2B608
P2860
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@ast
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@en
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@nl
type
label
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@ast
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@en
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@nl
prefLabel
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@ast
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@en
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@nl
P2860
P921
P356
P1476
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
@en
P2093
Michael A Nauck
P2860
P304
P356
10.2147/DDDT.S50773
P407
P5008
P577
2014-09-11T00:00:00Z